Skip to main content
Fig. 4 | BMC Infectious Diseases

Fig. 4

From: HIV-1 Tat protein vaccination in mice infected with Mycobacterium tuberculosis is safe, immunogenic and reduces bacterial lung pathology

Fig. 4

Tat vaccine enhances systemic IFN-γ and IL-17 responses specific for mycobacterial antigens in both Mtb-infected and BCG-vaccinated, Mtb-free mice. Spleen cells of Mtb-infected (a-c) or Mtb-free (d-f) mice treated as shown in Fig. 1 were stimulated ex vivo with 5 μg/ml of rAg85B protein or 2 μg/ml of PPD for 96 h. Culture supernatants were assayed for production of IFN-γ (a, d, Ag85B stimulation; b, e, PPD-stimulation) or IL-17 (c, f) by commercial ELISA kits. Each data point represents a pool of 5 or 6 mice, assessed in technical duplicates or triplicates and represents the mean ± SEM. The results shown are representative of two independent experiments. Statistical analysis was done by two-way ANOVA and Tukey’s multiple-comparison post-test*, P < 0.05, **, P < 0.01, ***, P < 0.001, ****, P < 0.0001, differences respect to untreated Mtb-infected group (a-c) or to untreated Mtb-free group (d-f). In panels d-f, the differences between BCG Tat-treated group versus both BCG and BCG buffer groups are indicated

Back to article page